Approval · Notice of Compliance 19290 · 2017
OPDIVO: Notice of Compliance 19290
Issued May 12, 2017
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 19290
- Date
- May 12, 2017
- Company
- Bristol-Myers Squibb CanadaSt-Laurent, Quebec, Canada
- Product type
- Biologic
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Priority
- Reason
- New indication: opdivo is indicated for the treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (scchn) in adults progressing on or after platinum-based therapy.
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| OPDIVO | Not yet assigned | — |